[Randomized phase II study with VP-16-213 (etoposide) in the treatment of advanced breast cancer].
Thirty patients with an advanced and previously heavily pretreated breast cancer were treated in a randomized phase II trial with the new podophyllotoxinderivative VP-16-213. The therapeutic result can be assessed in 28 cases. Half of these patients received the cytotoxic drug orally 150 mg/m2/day during 5 days once every 3 weeks. The other half were randomized to receive the drug i.v. 150 mg/m2 weekly. No clear-cut partial remission was detected among the treated patients. In 3 cases a tumor regression was observed, which only met the criteria for a minor regression. These data are consistent with the single agent activity reported in the literature, which encompass mostly heterogeneous series with a few patients. The antitumoractivity of VP-16-213 in the treatment of breast cancer seems to be moderate. However, this should not prevent its incorporation into future, suitable combination chemotherapies.
D000284:Administration, Oral; D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011379:Prognosis; D011897:Random Allocation
D005047:Etoposide; D011034:Podophyllotoxin
Randomisierte Phase-II-Studie mit VP-16-213 (Etoposide) in der Behandlung vom fortgeschrittenen Mammakarzinom.